BeOne Medicines (ONC) Non-Current Deffered Revenue (2017 - 2023)

BeOne Medicines (ONC) has 6 years of Non-Current Deffered Revenue data on file, last reported at $300000.0 in Q4 2023.

• On a quarterly basis, Non-Current Deffered Revenue fell 99.29% year-over-year to $300000.0 in Q4 2023; TTM through Dec 2023 was $300000.0, a 99.29% decrease from a year earlier, with the FY2023 full-year figure at $300000.0, down 99.29% from the prior year.
• Non-Current Deffered Revenue for Q4 2023 stood at $300000.0, roughly flat from $300000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for ONC reached as high as $220.3 million in Q4 2021 and fell as low as $300000.0 in Q3 2023.
• Historically, Non-Current Deffered Revenue has averaged $81.6 million across 4 years, with a median of $52.3 million in 2021.
• Across the five-year window, Non-Current Deffered Revenue jumped 186.77% in 2022 and tumbled 99.8% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $8.2 million in 2019, then soared by 2573.41% to $220.3 million in 2021, then slumped by 80.92% to $42.0 million in 2022, then sank by 99.29% to $300000.0 in 2023.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $300000.0 in Q4 2023, $300000.0 in Q3 2023, and $24.3 million in Q2 2023.